Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sharleen St Surin-Lord

Procedural Dermatology Largo, MD Medical Doctor

NPI 1023288156 CMS profile 933514

1400 Mercantile Ln, Suite 110, Largo, MD 20774

Open in the dashboard

General payments

$219,274

746 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$655,175 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sharleen St Surin-Lord of Largo, MD is reported in the CMS Open Payments database as having received $219,274 across 746 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $655,175 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,971 168
2024 General $16,571 38
2023 General $49,545 62
2022 General $30,875 93
2021 General $19,727 82
2020 General $27,092 110
2019 General $35,494 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharleen St Surin-Lord
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Sharleen St Surin-Lord were reported at $39,971. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Sharleen St Surin-Lord Procedural Dermatology median Middle half National median
2019 $35,494 $454 $152–$1,260 $163
2020 $27,092 $243 $90–$835 $114
2021 $19,727 $337 $102–$1,128 $132
2022 $30,875 $443 $119–$1,654 $149
2023 $49,545 $583 $137–$1,838 $160
2024 $16,571 $611 $132–$1,835 $164
2025 $39,971 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $160,258 204 payments
  2. Pfizer Inc. $35,891 79 payments
  3. Ortho Dermatologics, a division of Bausch Health US, LLC $16,515 70 payments
  4. Medimetriks Pharmaceuticals, Inc. $1,523 63 payments
  5. Mayne Pharma Inc. $1,514 136 payments
  6. AbbVie, Inc. $547 26 payments
  7. UCB, Inc. $413 22 payments
  8. LEO Pharma Inc. $389 45 payments
  9. Genzyme Corporation $383 12 payments
  10. Novartis Pharmaceuticals Corporation $231 15 payments
  11. Other $1,611 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $158,485 75 payments
  2. Consulting Fee $32,830 10 payments
  3. Food and Beverage $17,126 630 payments
  4. Travel and Lodging $10,830 30 payments
  5. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. AKLIEF Acne $90,636 89 payments
  2. TWYNEO $52,564 49 payments
  3. ORACEA $29,626 25 payments
  4. EPSOLAY $24,277 18 payments
  5. CIBINQO $22,544 50 payments
  6. NEMLUVIO $21,071 32 payments
  7. EPIDUO FORTE $18,759 29 payments
  8. ALTRENO $15,939 14 payments
  9. EUCRISA $12,094 47 payments
  10. AKLIEF Acne $4,227 3 payments
  11. Other $8,745 463 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

428

Median for Dermatology: 534

Drug cost

$19,748

Median for Dermatology: $67,151

Branded share of claims

11.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 77 $4,401
Tacrolimus Generic 15 $2,780
Fluocinonide Generic 64 $2,501
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 20 $1,591
Tretinoin Generic 24 $1,572
Ketoconazole Generic 69 $1,526
Retin-A Tretinoin Brand 29 $1,212
Calcipotriene Generic 14 $1,101
Desonide Generic 17 $1,012
Ciclopirox Generic 25 $880

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$30,349

Of which drugs: $97

Medicare patients

157

Average age 74

Services billed

503

128 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 37%
Chronic kidney disease 22%
Ischemic heart disease 17%
Cancer 16%
Osteoporosis 12%
Atrial fibrillation 8%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 137 $97

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AKLIEF
  • Galderma Laboratories, L.P. $12,531
$12,531 — —
DUPIXENT
  • GENZYME CORPORATION $76
  • Regeneron Healthcare Solutions, Inc. $40
$116 — —
CIBINQO
  • PFIZER INC. $49
$49 — —
Tovet (emollient formulation)
  • Medimetriks Pharmaceuticals, Inc. $49
$49 — —
LITFULO
  • PFIZER INC. $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

746 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record